AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00882739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel 300 mg
Description: Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
Study NCT00882739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Description: Patients will receive a 600 mg clopidogrel loading dose at first medical contact
Study NCT00882739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg
Description: Patients will receive a 900 mg clopidogrel loading dose at first medical contact
Study NCT04190797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + patiente controled anaethesia (PCA)
Description: Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
Study NCT01500473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel
Description: Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
Study NCT01106079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive management or Tight control
Description: Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
Study NCT01106079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard management - Control group
Description: The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
Study NCT02032680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based multi-family psychoeducational treatment
Description: This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
Study NCT02032680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-persons Multi-Family Group Psycho-Education treatment
Description: This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
Study NCT02032680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
Study NCT00435760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: 200 micrograms, once daily, 1 day treatment
Study NCT00435760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tiotropium
Description: 1 puff once daily, 1 day treatment
Study NCT00435760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
Study NCT04190797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + patiente controled anaethesia (PCA)
Description: Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
Study NCT01976260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Radiofrequency
Study NCT01976260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1550-nm Fractional Photothermolysis
Study NCT02983994 — intervention group
Intervention type: DEVICE
Intervention: TURBUHALER®
Study NCT02983994 — intervention group
Intervention type: DEVICE
Intervention: SPIROMAX®
Study NCT02391493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds).
Study NCT04147936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1665
Description: Dietary supplement: AXA1665
Study NCT03902535 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Complete comprehensive geriatric assessment
Study NCT03902535 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment
Study NCT04147936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01467388 — intervention group
Intervention type: PROCEDURE
Intervention: selective laser trabeculoplasty (SLT)
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Study NCT03902535 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT02659319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Lifestyle (FL)
Description: 12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
Study NCT05654155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
Study NCT05654155 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: auricular acupressure
Description: Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
Study NCT04919577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: X-ray
Description: We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
Study NCT04477811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1
Description: vitamin k1 tablets
Study NCT04477811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin k2
Description: vitamin k2 45 ug tablets twice daily
Study NCT04477811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study NCT03753347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2018-19 quadrivalent inactivated influenza vaccine
Description: A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
Study NCT00369512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
Study NCT03403816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Before School Physical Activity Program
Description: BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
Study NCT01314261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study NCT00446407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care Intervention
Description: Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
Study NCT01314261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study NCT02659319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dynamics (FD)
Description: The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
Study NCT02659319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group (PG)
Description: Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
Study NCT02653716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Orleans Intervention Method
Description: An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
Study NCT02653716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
Study NCT02645617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varnish
Description: Topical application to the teeth
Study NCT03389737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Counseling on healthy behaviors with in person meetings.
Study NCT03389737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Counseling on healthy behaviors with emails.
Study NCT01314261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT01314261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study NCT01314261 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-267
Description: Participants received matching placebo tablet at each dose level for ABT-267.
Study NCT02608099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted apixaban
Description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Study NCT02608099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Description: Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Study NCT01475981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition
Study NCT00875940 — intervention group
Intervention type: OTHER
Intervention: Diagnostic imaging procedures.
Study NCT02337725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012
Description: TVP-1012 1mg Tablets
Study NCT02337725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT02917915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canadian Standardized PR
Description: Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
Study NCT02917915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional PR
Description: Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
Study NCT04083755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose Injection [Injectafer]
Description: 1000mg intravenous
Study NCT04083755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no treatment or oral iron supplementation
Description: No treatment or treatment oral with iron supplementation if iron-deficiency anemia
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heroin
Description: Heroin (25 mg)
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: .4 mg
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Bup Dose
Description: 4 and 8 mg
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Bup Dose
Description: 8mg and 16 mg
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Bup/Nal Dose
Description: Buprenorphine/Naloxone 4/1 mg, 8/2 mg
Study NCT00435760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LAS34273
Description: 1 puff, 1 dat treatment
Study NCT03793127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maximal oxygen consumption (V02 max)
Description: Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
Study NCT03793127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brown adipose tissue (BAT) imaging
Description: Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
Study NCT03793127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle function testing
Description: This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Bup/Nal Dose
Description: Buprenorphine/Naloxone 8/2 mg, 16/4 mg
Study NCT00710385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PCB)
Description: Placebo control administration
Study NCT01851785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) Intervention
Description: Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?
Study NCT01152177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic reminder letters
Description: Electronic reminder letters if adherence is not obtained (up to four)
Study NCT01468636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Zinc
Description: 200 mg BID of oral zinc gluconate x 8 weeks
Study NCT01468636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID x 8 weeks
Study NCT00548236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based exercise intervention
Description: Exercise counselling offered via telephone calls
Study NCT02198690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mammography decision aid
Study NCT02198690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home safety pamphlet
Study NCT04039867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin with Gemcitabine
Description: Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
Study NCT01399268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
Study NCT01399268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
Study NCT00209898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast initiation procedure
Study NCT00651625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001
Description: The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
Study NCT00651625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional syringe - BD Ref 309604
Description: the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
Study NCT01475981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition
Study NCT04045431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAAG-OA
Description: Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
Study NCT04045431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Intra-articular injection of 6ml Synvisc-One in the target knee
Study NCT03037489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered orally once daily
Study NCT03272672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Össür Unloading Knee Brace
Description: During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment.
Study NCT02576652 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tetracycline
Description: Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
Study NCT02576652 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Demeclocycline
Description: Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
Study NCT02576652 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Hip Replacement
Description: Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.